Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. develops novel biologic antibody programs for inflammatory and immunology diseases, with disclosed focus areas including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its programs target established mechanisms of action and use antibody engineering intended to optimize half-life and dosing properties.
Recurring APGE news includes clinical data and pipeline updates for zumilokibart (APG777), APG279, which combines zumilokibart with APG990, and APG333. Company updates also cover operating and financial results, public equity offerings, management conference participation, shareholder-voting matters, governance changes and financing activity to support preclinical studies, clinical trials, manufacturing, commercial readiness and general corporate purposes.
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech company focused on developing biologics for atopic dermatitis, COPD, asthma, and other inflammatory and immunology conditions, announced its participation in two upcoming investor conferences. The Jefferies Global Healthcare Conference will take place on June 6, 2024, at 8:30 a.m. ET, followed by the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 11:20 a.m. ET. Live and archived webcasts of these events will be accessible through the company's website.
Apogee Therapeutics announced the dosing of the first patient in its Phase 2 trial of APG777 for atopic dermatitis (AD). APG777 is a novel subcutaneous monoclonal antibody targeting IL-13, with a half-life extended to approximately 75 days. Phase 1 results indicated a potentially best-in-class profile. The Phase 2 study combines typical Phase 2a and 2b into a single protocol, with an expected 16-week proof-of-concept data in 2H 2025. The trial aims to improve clinical responses with fewer injections. APG777's potential for treating asthma and other inflammatory diseases is also being explored.
Apogee Therapeutics, a clinical-stage biotechnology company, reported pipeline progress and first quarter financial results. The company initiated Phase 2 trials for APG777 targeting atopic dermatitis, dosed the first participant in the Phase 1 trial for APG808 targeting chronic obstructive pulmonary disease, and selected a development candidate for APG990. Additionally, Apogee raised $483 million through a public offering, maintaining a cash position of $816 million. Despite positive pipeline advancements, the company reported an increase in R&D and G&A expenses resulting in a net loss of $32.1 million for the first quarter of 2024.
Apogee Therapeutics, a clinical-stage biotechnology company, will participate in the 2024 Bank of America Healthcare Conference. The CEO and CFO will engage in a fireside chat to discuss the company's advancements in biologics for various medical conditions. The event will be webcasted for investors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.